Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System

NCT: NCT07334691 · RECRUITING

NCT IDNCT07334691
StatusRECRUITING
Start Date2026-01-20
Completion2033-09

Brief Summary

This investigation is a continuation for "TARGET" investigation and its purpose is to further demonstrate the efficiency and safety of the Cardiovalve system in the treatment of subjects with tricuspid regurgitation. The same subject population will be included, while applying the clinical and scientific knowledge accumulated in the TARGET investigation. This investigation will support the submission for obtaining marketing approval.

Frequently Asked Questions

What is TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System?

TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System is a clinical trial registered under NCT07334691. Current status: RECRUITING.

What is the status of NCT07334691?

The current status of NCT07334691 (TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System) is: RECRUITING.

When did TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System start?

TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System started on 2026-01-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑